Investors

Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.

Latest results

Portfolio metrics

35+
Approved products
14
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration

Financial metrics

$3.0bn
Portfolio Receipts
(2023)
$2.8bn
Adjusted EBITDA
(2023)
$2.0bn
Average annual capital deployed (2018-2023)
$4.0bn
Announced value of transactions (2023)

Corporate presentation

SEC filings

Filing Date Form View
Loading…
All Filings

Latest releases

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe